
Opinion|Videos|December 6, 2024
AE Monitoring and Management With Targeted Therapies in NSCLC
Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.
Advertisement
Episodes in this series

- (Rohit asks Levy) Please briefly highlight other trials of note and how the treatment landscape in HER2-altered NSCLC may evolve over time. What might be the positioning of ADCs, TKIs, and other treatment modalities in the treatment landscapes for HER2-mutated and HER2-overexpressing NSCLC?
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
2
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
3
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
4
What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma
5



















































